Batten Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Batten Disease Market Outlook

Thelansis’s “Batten Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Batten Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Batten Disease Overview

Batten Disease, one of the rare genetic disorders, falls within the category of progressive degenerative neurometabolic disorders collectively known as neuronal ceroid lipofuscinoses. Human NCLs result from mutations in several genes, encompassing over 430 mutations. These genes play various roles, including encoding lysosomal enzymes (such as CLN1, CLN2, CLN10, and CLN13), a soluble lysosomal protein (CLN5), a protein involved in the secretory pathway (CLN11), two cytoplasmic proteins that also interact with membranes (CLN4 and CLN14), as well as multiple transmembrane proteins found in different subcellular locations (CLN3, CLN6, CLN7, CLN8, and CLN12). While most mutations in these genes typically manifest as a standard disease phenotype, some result in a wide range of disease onset, severity, and progression, leading to distinct clinical phenotypes. Within this spectrum, there remain disease subgroups for which the molecular genetic backgrounds remain unknown. The initial symptom typically emerges as progressive visual impairment between the ages of 4 and 7, ultimately resulting in blindness within 2 to 10 years due to pigmentary retinopathy. For an extended period, patients are primarily identified as visually impaired. However, over time, patients also exhibit progressive cognitive decline and behavioral issues, including episodes of anger, physical aggression, and anxiety with depressive features. Seizures typically develop around ten, primarily in generalized tonic-clonic seizures.

• Batten Disease affects approximately 4.2 to 7.5 cases per 100,000 live births in the United States and 2.4 to 4.1 cases per 100,000 live births in Europe.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: